Sequoia Financial Advisors LLC Lowers Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Sequoia Financial Advisors LLC lessened its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 11.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,935 shares of the company’s stock after selling 1,133 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Prestige Consumer Healthcare were worth $547,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Trexquant Investment LP raised its position in Prestige Consumer Healthcare by 109.1% in the 3rd quarter. Trexquant Investment LP now owns 8,340 shares of the company’s stock worth $477,000 after buying an additional 4,351 shares during the last quarter. Qube Research & Technologies Ltd grew its stake in shares of Prestige Consumer Healthcare by 91.4% during the 3rd quarter. Qube Research & Technologies Ltd now owns 72,092 shares of the company’s stock valued at $4,123,000 after purchasing an additional 34,430 shares during the period. SG Americas Securities LLC bought a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter valued at about $1,632,000. Connors Investor Services Inc. bought a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter valued at about $1,569,000. Finally, Hsbc Holdings PLC grew its stake in shares of Prestige Consumer Healthcare by 17.1% during the 3rd quarter. Hsbc Holdings PLC now owns 22,075 shares of the company’s stock valued at $1,263,000 after purchasing an additional 3,226 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 5,336 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $69.00, for a total value of $368,184.00. Following the completion of the transaction, the senior vice president now directly owns 15,934 shares in the company, valued at approximately $1,099,446. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.60% of the stock is currently owned by corporate insiders.

Prestige Consumer Healthcare Trading Down 0.1 %

Shares of NYSE:PBH opened at $68.06 on Wednesday. The stock has a 50 day moving average of $70.58 and a 200 day moving average of $63.61. The company has a market cap of $3.38 billion, a PE ratio of -41.50, a price-to-earnings-growth ratio of 1.85 and a beta of 0.52. The company has a current ratio of 3.09, a quick ratio of 1.92 and a debt-to-equity ratio of 0.75. Prestige Consumer Healthcare Inc. has a 12-month low of $55.96 and a 12-month high of $75.31.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, February 8th. The company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.04 by $0.02. The company had revenue of $282.74 million during the quarter, compared to the consensus estimate of $280.25 million. Prestige Consumer Healthcare had a positive return on equity of 14.09% and a negative net margin of 7.11%. The firm’s revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the company posted $1.04 EPS. As a group, equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.33 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on PBH shares. TheStreet upgraded Prestige Consumer Healthcare from a “c+” rating to a “b-” rating in a research note on Monday, February 12th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, February 10th. One research analyst has rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Prestige Consumer Healthcare currently has an average rating of “Moderate Buy” and an average price target of $110.00.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.